Stockscreener 앱 받기
76.20
1.58%
1.43
Dexcom Inc 주식(DXCM)의 최신 뉴스
A Watch on DexCom: Expanding Access and Innovation Drive the Next Chapter of CGM Leadership - Kalkine
3 Reasons Investors Love DexCom (DXCM) - Yahoo Finance
Pharmsource says it was unaware Dexcom sensors it bought were slated for destruction - Reuters
Goodman Advisory Group LLC Invests $1.29 Million in DexCom, Inc. $DXCM - MarketBeat
DexCom Says Diabetes Tech Issue Isn't Investor Fraud - Law360
TD Cowen Remains a Buy on Dexcom (DXCM) - The Globe and Mail
DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Dexcom Inc. stock (US2521311074): TD Cowen lifts target after strong Q1 momentum - AD HOC NEWS
Here's why you should retain DexCom stock in your portfolio - MSN
TD Cowen raises DexCom stock price target to $95 on data - Investing.com
TD Cowen Adjusts Price Target on DexCom to $95 From $75, Maintains Buy Rating - marketscreener.com
Motley Fool Asset Management LLC Raises Stake in DexCom, Inc. $DXCM - MarketBeat
DexCom Inc (DXCM)'s Winning Formula: Financial Metrics and Compe - GuruFocus
Is DexCom stock underperforming the Dow? - MSN
DXCM to launch Dexcom Flex CGM system for type 2 diabetes in Germany - MSN
Dexcom stock (US2521311074): Mizuho lifts target after diabetes study - AD HOC NEWS
Pumps, patches and fixes at the ADA - BioWorld News
Dexcom bolsters evidence for glucose sensors for Type 2 diabetes - MedTech Dive
Devon Energy Corp stock (US2521311074): Dividend, oil price moves and what matters for investors - AD HOC NEWS
Mizuho raises Dexcom stock price target to $85 on diabetes study - Investing.com
Raymond James Adjusts Price Target on DexCom to $91 From $81, Maintains Strong Buy Rating - marketscreener.com
DexCom Inc. stock outperforms competitors on strong trading day - MSN
DexCom Inc (DXCM) Stock Up 5.2% and Still Undervalued -- GF Scor - GuruFocus
Dexcom reports positive CONNECT data for non-insulin diabetes - MSN
Clinical Wins Boost Dexcom Growth Story In Type 2 DiabetesDexCom (NASDAQ:DXCM) - Benzinga
DexCom, Inc. (DXCM) latest stock news and headlines - Yahoo Finance Singapore
DexCom Reports Positive CONNECT Data for Non-Insulin Diabetes - Yahoo Finance Singapore
DexCom jumps as new ADA trial data boosts optimism for broader CGM adoption - Quiver Quantitative
Why is DexCom stock surging today? By Investing.com - Investing.com Canada
Mizuho Securities Adjusts DexCom Price Target to $85 From $75, Maintains Outperform Rating - marketscreener.com
DexCom, Inc. (DXCM): Investor Outlook Reveals 13.92% Potential Upside In Continuous Glucose Monitoring Market - DirectorsTalk Interviews
DexCom (DXCM) Reports Positive Trial Results for Glucose Control in Type 2 Diabetes - GuruFocus
Is It Time To Reassess DexCom (DXCM) After Recent Glucose Monitoring Headlines? - Sahm
Dexcom G7 gave Type 2 adults 5 extra hours a day in range - Stock Titan
Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin - The AI Journal
Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study - Reuters
Assessing DexCom (DXCM) Valuation After Recent Share Price Momentum - Yahoo Finance
Insider Selling: DexCom (NASDAQ:DXCM) EVP Sells 4,912 Shares of Stock - MarketBeat
Dexcom (DXCM) EVP Jon Coleman sells 9,823 shares in planned trades - Stock Titan
Dexcom buys Nutrisense; Insulet rolls out patch pump update - MedTech Dive
Stifel Adjusts Price Target on DexCom to $90 From $85, Maintains Buy Rating - marketscreener.com
Is DexCom Stock Underperforming the Dow? - Yahoo Finance
DXCM News | DEXCOM INC (NASDAQ:DXCM) - ChartMill
DXCM (NASDAQ: DXCM) affiliate files Form 144; director sold 4,912 shares - Stock Titan
Here's Why You Should Retain DexCom Stock in Your Portfolio - The Globe and Mail
[Latest] Non-Invasive Blood Glucose Monitoring Devices Market Size to Hit USD 340.49 Million with a Promising CAGR of 25.60% by 2034 - GlobeNewswire Inc.
DexCom (DXCM) Showcases Innovations and Future Plans at ADA Scie - GuruFocus
Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026 - StreetInsider
DexCom vs. Insulet: Growth Trajectories and Valuations for InvestorsNews and Statistics - IndexBox
DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026? - Yahoo Finance
1.68%
0.42%
자본화:
|
볼륨(24시간):